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Abstract Insulin degludec/insulin aspart (IDegAsp; 70 %
IDeg and 30 % IAsp) is a soluble combination of two
individual insulin analogues in one product, designed to
provide mealtime glycaemic control due to the IAsp
component and basal glucose-lowering effect from the
IDeg component. The pharmacokinetic and pharmacody-
namic characteristics of IDegAsp have been investigated in
a series of clinical pharmacology studies with generally
comparable designs, methodologies and patient inclusion/
exclusion criteria. The glucose-lowering effect profile of
IDegAsp during once-daily dosing at steady state shows
distinct and clearly separated action from the prandial and
basal components of IDegAsp. The IAsp component pro-
vides rapid onset and peak glucose-lowering effect fol-
lowed by a flat glucose-lowering effect lasting beyond 30 h
due to IDeg. During twice-daily dosing, the distinct peak
effect and the flat basal effect are retained following each
dose. The pharmacological properties of IDegAsp are
maintained in the elderly, children, adolescents, Japanese
patients and those with hepatic or renal impairment. The
potential clinical benefits associated with the pharmaco-
logical properties of IDegAsp have been verified in phase
III clinical trials comparing IDegAsp with three other
currently available treatment options: premixed insulin,
basal-bolus regimens and basal-only therapy. IDegAsp
shows favourable clinical benefits compared with biphasic
insulin aspart 30 and is a viable alternative to basal-bolus
and basal-only therapy. This review presents the results
from clinical pharmacology studies conducted with
IDegAsp to date, and extrapolates these results to clinical
use of IDegAsp in the context of findings from the
IDegAsp clinical therapeutic studies.
Key Points
There is a clinical need for an insulin combination
that can offer both basal and mealtime insulin
coverage in one injection in patients with diabetes.
Insulin degludec/insulin aspart (IDegAsp; 70 %
IDeg and 30 % IAsp) provides rapid onset and peak
glucose-lowering effect due to the bolus IAsp
component, as well as a flat and long-lasting glucose-
lowering effect from the basal IDeg component,
during both once- and twice-daily dosing across
several different patient populations.
Due to its pharmacological properties, IDegAsp is
superior to premixed formulations and may also be
an alternative to basal-only and basal-bolus therapy.
1 Introduction
Patients with type 2 diabetes mellitus (T2DM) receiving
basal insulin who require additional mealtime insulin can
intensify treatment either through the addition of mealtime
short-acting insulin or by switching to a premixed insulin
formulation [1]. Basal-plus (i.e. the addition of one or two
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mealtime injections) or full basal-bolus regimens approach
the physiological basal and mealtime insulin responses,
albeit with the complexity of up to four or five separate
injections. Such treatment regimens with multiple daily
injections and frequent blood glucose sampling can be
challenging for patients and may decrease treatment
adherence [1–3]. Premixed insulin formulations, which
cover both basal and mealtime insulin needs in one injec-
tion, offer a more convenient alternative, although are
relatively inflexible in terms of titration and timing and
need to be resuspended before administration, which is an
additional burden for patients and is often done incorrectly
[1, 4–6]. Although premixed insulin products have pro-
vided a simpler treatment option for patients requiring
better glycaemic control, and are widely used globally [7],
premixed insulin products also carry limitations in their
pharmacokinetic and pharmacodynamic properties, as dis-
cussed in Sect. 2 of this review. Therefore, there has been a
clinical need for a combined insulin formulation that can
provide sustained and stable basal insulin coverage toge-
ther with an effective mealtime bolus dose in one injection.
Insulin degludec/insulin aspart (IDegAsp) is the first
soluble combination of two different insulin analogues
(70 % IDeg and 30 % IAsp), providing long and steady
basal glucose-lowering effect due to the IDeg component,
and mealtime glycaemic control due to the rapid absorption
of the IAsp component in a single pen [8]. The pharma-
cokinetic and pharmacodynamic characteristics of
IDegAsp have been investigated in a series of studies,
which have shown improvements in pharmacological
properties compared with premixed insulin products
[9–13]. Furthermore, the potential clinical benefits associ-
ated with these properties have been verified in large phase
III clinical trials [14–21]. This review discusses the results
obtained from the pharmacokinetic and pharmacodynamic
studies conducted with IDegAsp to date, and extrapolates
the clinical relevance of the observed pharmacokinetic and
pharmacodynamic properties of IDegAsp in the context of
the findings from the IDegAsp clinical therapeutic studies.
2 Insulin Formulations to Provide Both Basal
and Mealtime Coverage
2.1 Limitations of Current Premixed Insulin
Formulations
Current premixed insulin formulations include biphasic
human insulin, biphasic insulin aspart (BIAsp) and insulin
lispro mix [4]. All of these products contain a fixed pro-
portion of the soluble form of either human insulin, IAsp or
insulin lispro, with the remainder consisting of the corre-
sponding protaminated form. Thus, basal and mealtime
coverage is provided in one injection. However, there are
several limitations associated with premixed insulin for-
mulations. First, the need for adequate and consistent
resuspension in order to ensure accurate dosing may
introduce substantial variability in the pharmacokinetic and
pharmacodynamic response [6]. Second, although pro-
tamination results in a protracted absorption of insulin into
the circulation, protamination of short-acting insulin only
results in intermediate-acting insulin. Thus, the duration of
action of premixed insulin products is still shorter than for
basal insulin analogues such as insulin glargine (IGlar) and
insulin detemir (IDet) [22, 23]. Third, in premixed insulin
products, the protaminated fraction interferes with the
soluble fraction, leading to an undesired, prolonged
glucose-lowering effect from the soluble part, which
overlaps with the peak action of the protaminated fraction
at approximately 6 h, which is often denoted the ‘shoulder
effect’ [24, 25]. Fourth, formation of insulin-protamine
precipitates in the subcutaneous tissue after administration,
and subsequent release of insulin into the circulation,
represent processes that contribute to variability in both
level and duration of insulin action. These limitations may
translate into variability in glycaemic control from day to
day, incomplete 24-h coverage and, presumably, an
increased rate of hypoglycaemia with premixed insulin
compared with basal-plus and basal-bolus regimens
[26–28].
2.2 Challenges of Combining a Basal and a Bolus
Insulin in a Single Formulation
The ideal way of providing basal and mealtime insulin
coverage in one injection would be to combine a basal and
a rapid-acting insulin, in a formulation where the two
components act independently, i.e. where the pharmaco-
logical properties of both components are preserved.
However, prior attempts to combine basal and rapid-acting
insulin analogues have been unsuccessful [29, 30].
In order to remain stable in the pen, rapid-acting insulin
analogues need to be formulated as a neutral solution, i.e.
with a pH of approximately 7.4 [8]. On the other hand,
IGlar requires formulation at acidic pH 4 to stay soluble
in the pen. Following subcutaneous administration, due to
the shift to physiological pH, IGlar forms microprecipi-
tates in the subcutaneous tissue, from which IGlar slowly
dissolves into the circulation [31]. Thus, the mode of
protraction for IGlar prevents it from co-formulation with
rapid-acting insulin analogues without any impact on the
glucose-lowering effect profile of the latter. Indeed, the
combination of IGlar and insulin lispro has been shown to
change the early glucose-lowering effect profile, resulting
in a reduced peak effect and a general right-shift of the
bolus-related effect profile [29].
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IDet, however, is formulated as hexamers in a neutral
solution (pH 7.4). Subcutaneous injection of IDet leads to
dilution of the preservatives present in the pharmaceutical
formulation (phenol, cresol and polyol), and hexameric
IDet then reaches a hexamer–dihexamer equilibrium [32].
The self-association into dihexamers and the binding to
albumin result in protraction of absorption into the circu-
lation [32]. When IDet is co-formulated with IAsp, the self-
association equilibriums for the two components may lead
to the formation of IDet/IAsp hybrid hexamers, which
would, in particular, limit the rapid absorption of IAsp [8].
Accordingly, an attempt to combine IDet and IAsp resulted
in a reduced and right-shifted early glucose-lowering effect
[30].
2.3 Combination of IDeg and IAsp in a
Co-Formulation (IDegAsp)
IDeg is the most recently developed basal insulin analogue
and has been approved in the EU, US and several other
countries worldwide [33, 34]. In the pharmaceutical for-
mulation, IDeg exists as highly stable dihexamers in a
neutral solution in the presence of phenol and zinc [35].
Upon injection, phenol diffuses and IDeg undergoes a
conformational change, leading to formation of soluble
multihexamers at the site of injection [35, 36]. Following
the gradual diffusion of zinc, the IDeg multihexamers
continuously disassemble and release monomers for
absorption into the circulation [35]. The stable IDeg
dihexamers in the pharmaceutical formulation and the
unique multihexamer formation in the subcutaneous tissue
made IDeg a promising candidate for co-formulation with
IAsp without the risk of hybrid hexamer formation. The
association states of IDeg and IAsp in a 70/30 % co-for-
mulation were investigated through size exclusion chro-
matography (SEC) studies in conditions simulating the
pharmaceutical formulation and the subcutaneous tissue
[8]. When IAsp was added to fully dihexameric IDeg in the
presence of high concentrations of zinc, the two compo-
nents coexisted in the formulation as separate molecular
entities (IDeg dihexamers and IAsp hexamers, respec-
tively) (Fig. 1a, left panels and 1b). In simulations of the
subcutaneous tissue depot, the two components also eluted
separately (as IDeg multihexamers and IAsp monomers,
respectively) (Fig. 1a, right panels). This suggests that
following subcutaneous administration of IDegAsp, the
formation of IDeg multihexamers and the disassembly of
IAsp from hexamers to monomers occur as discrete pro-
cesses (Fig. 1c) [8]. Hence, for the first time, a combination
of two separate insulin analogues (IDeg and IAsp) has been
made possible without changing the pharmacological
properties of the individual components. It is important to
realise that IDegAsp clearly differentiates from premixed
insulin products due to the existence of its insulin com-
ponents as separate and stable soluble forms in the for-
mulation, thereby avoiding the need for resuspension prior
to injection.
3 Pharmacodynamic Characteristics of IDegAsp
3.1 Data Collection Procedures
In the clinical pharmacology studies investigating the
pharmacological properties of IDegAsp, study designs,
methodologies and patient inclusion/exclusion criteria
were generally standardised and studies were conducted at
a limited number of sites to maintain consistency in data
collection and analysis.
The ‘gold standard’ to evaluate the pharmacodynamic
properties of exogenous insulin is the euglycaemic glucose
clamp. This measures the rate of intravenous glucose
infusion needed to maintain the blood glucose concentra-
tion at a constant, predetermined, normal level following
insulin administration, and uses this rate as a measure of
the glucose-lowering effect of the exogenous insulin under
investigation [37, 38]. Patients with type 1 diabetes mel-
litus (T1DM) are the optimal population to evaluate the
pharmacodynamic characteristics of exogenous insulin as
the euglycaemic clamp results are not affected by
endogenous insulin secretion (as would be the case in
healthy volunteers or patients with T2DM) or acquired
insulin resistance (as would be the case in patients with
T2DM).
3.2 Glucose-Lowering Effect of IDegAsp
The pharmacodynamic properties of IDegAsp have been
investigated during once-daily dosing at steady state in a
30-h euglycaemic glucose clamp in patients with T1DM
[9].
The glucose-lowering effect profile of IDegAsp showed
distinct and clearly separated action from the prandial and
basal components of IDegAsp (Fig. 2). The IAsp compo-
nent provided rapid onset and peak glucose-lowering
effect, thereby ensuring mealtime coverage. Subsequently,
a flat and long-lasting glucose-lowering effect from IDeg
persisted for longer than the clamp duration of 30 h in all
patients. These pharmacodynamic properties are consistent
with what has been shown for the individual IAsp and IDeg
components [39–42], thus supporting the pharmacokinetic
results showing that absorption of IAsp and IDeg is
essentially unaffected by their co-formulation in IDegAsp
(see Sect. 4.3).
As a consequence of the extended duration of action of
IDeg, well beyond 24 h in all patients [41, 43], the glucose-
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lowering effect of IDeg builds up during the first days of
once-daily dosing and reaches a plateau within 2–3 days
[44]. For the same reason, the steady-state glucose-lowering
effect of IDegAsp is increased compared with
single-dose treatment. This has been shown by comparing
the glucose-lowering effect profiles of 0.6 U/kg IDegAsp
after single dose [10] and at steady state [9]. As expected, a
parallel upshift in the glucose-lowering effect profile from
single dose to steady state occurred, with no change in the
shape and size of the bolus-related initial peak corre-
sponding to the mealtime coverage (Fig. 3).
The results of a dose–response study in patients with
T1DMwith single doses of IDegAsp (0.4, 0.6 and 0.8 U/kg)
supported dose proportionality for the glucose-lowering
effect, since the 95 % confidence interval (CI) for the log-
dose slope for both the glucose-lowering effect over 24 h
(AUCGIR,0-24h ; log-dose slope 1.19, 95 %CI 0.99–1.40) and
maximum glucose-lowering effect (GIRmax; log-dose slope
0.89, 95 % CI 0.66–1.13) included 1.00 [10, 45].
3.3 Glucose-Lowering Effect of IDegAsp Compared
with Biphasic Insulin Aspart 30 (BIAsp 30)
The single-dose glucose-lowering effect profiles have been
compared between IDegAsp and BIAsp 30 at three doses
(0.4, 0.6 and 0.8 U/kg) in patients with T1DM [10]. Since
both IDegAsp and BIAsp 30 contain rapid-acting IAsp, the
onset of action and shape of the glucose-lowering effect
profiles during the initial 4 h were similar for IDegAsp and
BIAsp 30, including comparable time to GIRmax (tGIRmax)
(Fig. 4). Beyond approximately 4 h, the glucose-lowering
effect of IDegAsp rapidly declined from its maximum peak
until approximately 6–7 h post-dose, followed by a flat and
stable action from the IDeg component. In contrast, the
glucose-lowering effect of BIAsp 30 steadily declined from
the peak level and approached zero approximately 18–22 h
post-dose, thus showing a ‘shoulder effect’ between 6 and
12 h post-dose attributable to the overlapping action of the
soluble and protaminated fractions of IAsp in BIAsp 30
(Fig. 4).
As discussed in Sect. 3.2, the steady-state glucose-
lowering effect of IDegAsp is greater than after a single
dose as a consequence of the long duration of action of
IDeg. In contrast, the glucose-lowering effect of BIAsp 30
returns to zero less than 24 h after dose administration, i.e.
before administration of the next dose in a once-daily dose
regimen. Consequently, the glucose-lowering effect profile
of BIAsp 30 after a single dose reflects clinical practice
during once-daily dosing, while this is not the case for
IDegAsp. For this reason, the absolute effects of single
doses of IDegAsp and BIAsp 30 must be compared with
caution. Both AUCGIR,0-24h as well as GIRmax were lower
after a single dose of 0.6 U/kg IDegAsp than after a single
dose of 0.6 U/kg BIAsp 30 [10]. As expected, at steady
state, both the AUCGIR,0-24h and the GIRmax for IDegAsp
were greater than after a single dose [9, 10]. However, it is
important to note that given the persistent shape of the
bFig. 1 Mode of absorption of IDegAsp. a Size-exclusion
chromatography of IDegAsp in conditions simulating the pharma-
ceutical formulation (left panels) and the subcutaneous environment
(right panels), and compared with separate IDeg and IAsp
formulations (using the same injection volume for both IDegAsp,
IDeg and IAsp). Going from left to right on the horizontal axis
indicates a shift from large multihexamers, through dihexamers and
hexamers, to monomers. Within each panel, the left and right peaks
are IDeg and IAsp, respectively. In the pharmaceutical formulation
(left panels), IAsp elutes almost solely as hexamers, and IDeg elutes
as dihexamers. In the subcutaneous environment (right panels), IAsp
elutes almost solely as monomers, and IDeg elutes as multihexamers
(modified from Havelund et al. [8]). b IDegAsp is a combination of
two soluble insulin analogues (30 % IAsp and 70 % IDeg) in one
pen. In the pen, IDeg forms soluble dihexamers at neutral pH, while
IAsp stays as hexamers. c Following subcutaneous administration, as
illustrated, IDeg dihexamers immediately self-associate to form
stable multihexamers in the subcutaneous tissue from which IDeg
monomers dissociate slowly and continuously. By contrast, IAsp
hexamers promptly dissociate to monomers and are then rapidly
absorbed into the circulation. IAsp insulin aspart, IDeg insulin
degludec, IDegAsp insulin degludec/insulin aspart




























Fig. 2 Mean glucose-lowering effect profile of IDegAsp adminis-
tered once daily at steady state in patients with T1DM (modified from
Heise et al. [9]. IDegAsp insulin degludec/insulin aspart, T1DM type 1
diabetes mellitus



























IDegAsp 0.6 U/kg SS
IDegAsp 0.6 U/kg SD
Fig. 3 Mean glucose-lowering effect profiles for 0.6 U/kg IDegAsp
after a single dose and at steady state during once-daily dosing in
patients with T1DM (modified from Heise et al. [10]). IDegAsp
insulin degludec/insulin aspart, SD single dose, SS steady state, T1DM
type 1 diabetes mellitus
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glucose-lowering effect profile of IDegAsp after a single
dose and at steady state (Fig. 3), single-dose comparisons
between IDegAsp and BIAsp 30 may be performed as long
as these only focus on the shape of the glucose-lowering
effect profiles rather than the absolute effect level.
3.4 IDegAsp Administered Twice Daily
IDegAsp may be administered once or twice daily with the
main meal(s) as per patient needs and lifestyle preferences
[46, 47]. The glucose-lowering effect profile of IDegAsp
administered twice daily at steady state has been studied by
simulationusing apharmacokinetic/pharmacodynamicmodel
based on data obtained in the study evaluating IDegAsp once
daily in patientswithT1DM[9]. The results suggested that the
distinct peak effect, aswell as the separate andflat basal effect,
were retained following each dose (Fig. 5).
The duration of action of IDegAsp is longer than 30 h as
a result of the extended duration of action of the IDeg
component [9]. It may be questioned whether such an
insulin product can be administered twice daily, as indi-
cated for IDegAsp, without the potential risk of ‘insulin
stacking’ [48]. Several lines of evidence alleviate such
concerns. First, several studies with IDeg have shown that
serum IDeg concentrations increase during the first days of
once-daily dosing, before reaching a plateau within
2–3 days. Thereafter, the exposure level of serum IDeg is
unchanged from day to day (Fig. 6a) [44]. Second, in a
multiple-dose regimen, the plateau levels of exposure and
effect depend only on the total daily dose rather than the
dosing frequency [49]. The dosing frequency only influ-
ences the peak-to-trough ratio, i.e. the difference between
the minimum and maximum concentration or effect within
a dosing interval [49]. This means that as long as the same
total daily IDegAsp dose is administered, once-daily versus
twice-daily dosing of IDegAsp at steady state will result in
the same total glucose-lowering effect over the day. The
total glucose-lowering effect originating from each of the
two components in IDegAsp will also remain unaffected.
The only differences will be that the peak-to-trough ratio
for the glucose-lowering effect of the basal IDeg compo-
nent will be smaller with twice-daily dosing, and that the
glucose-lowering effect of the IAsp component will be split
over two dose administrations (Fig. 6b). This can be seen
when comparing the 24-h glucose-lowering effect profiles
of 0.6 U/kg IDegAsp once daily (Fig. 2) and 0.3 U/kg
IDegAsp twice daily (Fig. 5).
3.5 Variability in Glucose-Lowering Effect
A common problem in the management of glucose
control is the need for exogenous insulin to provide the
same glucose-lowering effect from injection to injection
in the same individual, usually measured as the within-
subject variability in glucose-lowering effect [50, 51].
No studies have investigated the within-subject vari-
ability in glucose-lowering effect for IDegAsp. However,
since the pharmacodynamic properties of IDeg and IAsp
appear to not be affected by their co-formulation in
IDegAsp, the within-subject variability in glucose-lowering
effect for IDeg and IAsp separately should provide a good
indicator for IDegAsp also.
The within-subject variability in glucose-lowering effect
for IDeg has been compared with IGlar in patients with





























BIAsp 30 0.8 U/kg SD
BIAsp 30 0.6 U/kg SD
BIAsp 30 0.4 U/kg SD





























IDegAsp 0.8 U/kg SD
IDegAsp 0.6 U/kg SD
IDegAsp 0.4 U/kg SD
(a) (b)
Fig. 4 Mean glucose-lowering effect profiles for single doses of 0.4,
0.6 and 0.8 U/kg (a) IDegAsp and (b) BIAsp 30 in patients with
T1DM (modified from Heise et al. [10]). BIAsp 30 biphasic insulin
aspart 30, IDegAsp insulin degludec/insulin aspart, SD single dose,
T1DM type 1 diabetes mellitus



























IDegAsp 0.3 U/kg BID
Fig. 5 Simulated mean glucose-lowering effect profile for 0.3 U/kg
IDegAsp administered twice daily at steady state in patients with
T1DM (modified from Heise et al. [9]). BID twice daily, IDegAsp
insulin degludec/insulin aspart, T1DM type 1 diabetes mellitus
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T1DM who were treated with 0.4 U/kg IDeg or IGlar for
12 days and participated in a 24-h euglycaemic clamp at
steady state on days 6, 9 and 12 [52]. IDeg had four-times
lower within-subject variability in the total glucose-lowering
effect (coefficient of variation 20 vs. 82 %; p\ 0.0001)
compared with IGlar [52]. To put this further into context,
previous studies in patients with T1DM have shown
within-subject coefficients of variation for 24-h glucose-
lowering effect of 68, 48 and 27 % for neutral protamine
hagedorn (NPH) insulin, IGlar and IDet, respectively [53],
and 99 and 48 % for IGlar and protaminated insulin lispro,
respectively [54]. The relatively low within-subject vari-
ability for IDeg and IDet is likely because they are for-
mulated as solutions, they stay in solution after
subcutaneous injection, their protraction occurs via for-
mation of multi-/dihexamers and they both bind reversibly
to albumin in the circulation, thereby providing a buffer
effect [55].
One study investigating the within-subject variability in
glucose-lowering effect of IAsp reported that the within-
subject coefficient of variation was 16 % for GIRmax and
generally in the range of 10–20 % for various pharmaco-
dynamic endpoints in healthy volunteers [56]. These values
were comparable with those observed for regular human
insulin [56]. Altogether, the within-subject variability in
glucose-lowering effect of the individual components of
IDegAsp is reported to be low. It is therefore speculated
that IDegAsp will also have relatively low day-to-day
variability in glucose-lowering effect.
4 Pharmacokinetic Characteristics of IDegAsp
4.1 Pharmacokinetic Data Collection
In the studies investigating the pharmacokinetic properties
of IDegAsp, serum IDeg concentrations were measured by
a validated IDeg-specific enzyme-linked immunosorbent
assay (ELISA), while serum IAsp concentrations were






























































































0.6 U/kg 0.3 U/kg 0.3 U/kg
Fig. 6 Steady-state concept for
IDegAsp during once- and
twice-daily dosing. a When
IDegAsp is administered once
daily, the IDeg component
essentially reaches steady state
within 2–3 days due to the
approximately 25 h half-life for
IDeg. b At steady state, the
glucose-lowering effect from
the basal IDeg component is
similar regardless of whether
IDegAsp is administered once
or twice daily, as long as the
total daily dose of IDegAsp is
unchanged. IDeg insulin
degludec, IAsp insulin aspart,
IDegAsp insulin degludec/
insulin aspart
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It is important to emphasise that the serum concentrations
of IDeg and IAsp cannot be directly compared and are not
additive, as serum concentrations of IDeg and IAsp differ by
several orders of magnitude, due to the reversible albumin-
binding of IDeg in the circulation. This complicates the
translation from pharmacokinetic results on the individual
IDeg and IAsp components to pharmacodynamic results for
IDegAsp, and makes the clinical interpretation of pharma-
cokinetic results with IDegAsp difficult.
It is expected that the pharmacokinetic profiles of the
individual IDeg and IAsp components are preserved in the
IDegAsp co-formulation [8] (Sect. 4.3). Consequently,
pharmacokinetic results generated after dosing with IDeg
or IAsp alone would be representative for the pharma-
cokinetic properties of the two components in the IDegAsp
product. For these reasons, this review focuses on the
pharmacokinetic properties of IDegAsp to a limited extent
only. The reader is referred to review articles on the
pharmacokinetic properties of the separate IDeg and IAsp
products [57, 58].
4.2 Pharmacokinetic Properties of IDegAsp
Clinical steady state for IDeg is obtained within 2–3 days
of once-daily IDeg dosing [44], and therefore it can be
anticipated that also after 2–3 days of once-daily IDegAsp
dosing, clinical steady state will occur for the basal IDeg
component. In a multiple-dose study with IDegAsp in
patients with T1DM, exposure of the IDeg component was
evenly distributed across the 24-h dosing interval at steady
state, as indicated by a mean ratio of AUCIDeg,0-12h,SS/
AUCIDeg,s,SS of 0.51 [9].
The IAsp component in IDegAsp has a rapid onset of
appearance (9–14 min) and a time to maximum concen-
tration of approximately 80 min [9, 11], suggesting that
IAsp maintains its rapid absorption properties when com-
bined with IDeg in IDegAsp.
4.3 Pharmacological Implications of
Co-Formulating IDeg and IAsp
In order to investigate the impact of co-formulating IDeg and
IAsp on the pharmacokinetic and pharmacodynamic prop-
erties of each of the two components, a single-dose studywas
conducted comparing the administration of IDegAsp with
corresponding separate simultaneous administrations of
IDeg and IAsp [45]. Thus, dose levels of the two components
were matched to their respective fractions in IDegAsp (70 %
IDeg and 30 % IAsp). While the pharmacokinetic profile of
IDeg was unchanged by co-formulation with IAsp, the
pharmacokinetic profile of IAsp was slightly skewed to the
right [45]. However, there was no significant impact on
GIRmax or AUCGIR,0-6h, which both reflect the effect of the
IAsp component, or on AUCGIR,0-24h [45]. Furthermore, the
24-h glucose-lowering effect profiles were comparable fol-
lowing injection of IDegAsp and corresponding separate
simultaneous injections of IDeg and IAsp (Fig. 7).
5 Pharmacological Properties of IDegAsp Across
Different Patient Populations
5.1 Children and Adolescents with Diabetes
In a study comparing the pharmacokinetic and mealtime
pharmacodynamic properties of IDegAsp in children (aged
6–11 years) and adolescents (12–17 years) with those in
adults with T1DM, no apparent age-group differences were
observed in total plasma glucose-lowering effect of IDegAsp
or in maximum plasma glucose concentration in a 6-h
standardised meal test after single-dose administration of
0.5 U/kg IDegAsp [11] (Fig. 8). Furthermore, the onset of
appearance of IAsp in IDegAsp occurred equally early in all
age groups (9–14 min post-dosing), and IDeg was
detectable in serum for the whole pharmacokinetic sampling
period of 57 h in all subjects, independent of age. These
findings support that the rapid onset and distinct peak action
from the IAsp component, and the steady basal glucose-
lowering effect due to the IDeg component, as observed in
adult patients, are preserved in younger age groups. Total
exposure and/or maximum concentration of IDeg and IAsp
differed, to some extent, between children and adults [11].
These observed differences might be explained by a com-
bination of greater interindividual variability in exogenous
insulin exposure in children than in adults and the relatively
small sample size of the study [11].
It must be emphasised that guidelines from the Inter-
national Society for Pediatric and Adolescent Diabetes
(ISPAD) do not currently recommend administration of
premixed insulin formulations to children and adolescents


























Fig. 7 Mean glucose-lowering effect profiles for administration of
0.92 U/kg IDegAsp, and for separate simultaneous administrations of
0.28 U/kg IAsp and 0.64 U/kg IDeg in patients with T1DM. IAsp
insulin aspart, IDeg insulin degludec, IDegAsp insulin degludec/
insulin aspart, T1DM type 1 diabetes mellitus
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[59]. Accordingly, fixed combination products, where
individual components cannot be individually titrated, may
not always be appropriate for children, but could be used
under strict medical supervision in cases where replace-
ment of suboptimal dosing regimens and/or improve-
ment of treatment compliance is necessary [11].
5.2 Elderly Patients with Diabetes
In a euglycaemic clamp study evaluating the pharmaco-
logical properties of 0.5 U/kg IDegAsp administered as a
single dose in elderly patients, the distinct prandial and
basal glucose-lowering effects of IDegAsp observed in
younger adults were preserved in elderly patients
aged[65 yearswith T1DM[12] (Fig. 9a). TheAUCGIR,0-24h
was similar in elderly patients and in younger adults (mean
ratio of elderly/younger adults 1.01, 95 % CI 0.69–1.47)
and there were also no age-group differences in other
pharmacodynamic endpoints, such as AUCGIR,0-6h, GIRmax
and tGIRmax [12]. Likewise, the total exposure of both
IAsp and IDeg components were comparable between
elderly and younger adult patients [12].
Brunner et al. used a population pharmacokinetic/
pharmacodynamic model to simulate steady-state
glucose-lowering effect profiles from the single-dose
results, and showed comparable glucose-lowering effect of
IDegAsp in elderly and younger adult patients following
both once- and twice-daily dosing of IDegAsp [12]
(Fig. 9b, c). It may be concluded that, also in elderly
patients with diabetes, IDegAsp provides peak action due
to IAsp, as well as separate and sustained basal glucose-
lowering effect from IDeg.
5.3 Patients with Renal Impairment
No pharmacokinetic studies with IDegAsp have been
conducted to date in patients with renal impairment.
However, since the individual pharmacokinetic properties
of IDeg and IAsp are preserved in IDegAsp, pharmacoki-
netic results after dosing of IDeg or IAsp alone in patients
with renal impairment should also be representative for
IDegAsp. In T1DM patients with normal renal function or
different degrees of renal impairment, there were no sig-
nificant linear correlations between creatinine clearance
and any of the pharmacokinetic endpoints after a single
dose of 0.08 U/kg IAsp [60]. In subjects with normal renal
function, and in patients with mild, moderate or severe
renal impairment, or end-stage renal disease (ESRD), no









































Fig. 8 Mean plasma glucose profiles (and standard error of the mean)
in a 6-h meal test after single-dose administration of 0.5 U/kg
IDegAsp in children, adolescents and adults with T1DM (from
Biester et al. [11]). IDegAsp insulin degludec/insulin aspart, T1DM
type 1 diabetes mellitus
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Fig. 9 Mean glucose-lowering effect profiles after administration of
IDegAsp in elderly and younger adults with T1DM. a Following a
single dose of 0.5 U/kg IDegAsp. b At steady state during once-daily
dosing of 0.5 U/kg IDegAsp. c At steady state during twice-daily
dosing of 0.25 U/kg IDegAsp (modified from Brunner et al. [12]
under the terms of the Creative Commons Attribution-NonCommer-
cial 4.0 International License [http://creativecommons.org/licenses/
by-nc/4.0/]). BID twice daily, IDegAsp insulin degludec/insulin
aspart, OD once daily, SD single dose, SS steady state, T1DM type 1
diabetes mellitus
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significant relationship was found between creatinine
clearance and total exposure, maximum concentration or
clearance after administration of 0.4 U/kg IDeg [61]. In
addition, total exposure, maximum concentration and
clearance of IDeg were similar in patients with ESRD
compared with subjects with normal renal function, and
haemodialysis had no impact on the pharmacokinetic pro-
file of IDeg [61]. It is therefore concluded, based on
pharmacokinetic results for IDeg and IAsp, that dose
titration of IDegAsp can be performed with no special
precautions in patients with diabetes and renal impairment
compared with those having normal renal function.
5.4 Patients with Hepatic Impairment
No pharmacokinetic studies with IDegAsp have been
conducted to date in patients with hepatic impairment.
Thus, pharmacokinetic results after dosing of IDeg or IAsp
alone in patients with hepatic impairment may be consid-
ered as representative for IDegAsp in the following. In
subjects with normal hepatic function or patients with
different degrees of hepatic impairment, regression analy-
sis of several pharmacokinetic endpoints revealed no sig-
nificant linear correlations with Child–Pugh Score after a
single dose of 0.06 U/kg IAsp [60]. In patients with mild,
moderate or severe hepatic impairment, compared with
subjects with normal hepatic function, the protracted
pharmacokinetic properties of IDeg were maintained, with
no significant differences in absorption or clearance
between groups [62]. It is therefore concluded that dose
titration of IDegAsp needs no special precautions in
patients with diabetes and hepatic impairment compared
with those having normal hepatic function.
5.5 Japanese Patients with Diabetes
Race and ethnic background may influence the pharma-
cological properties of a drug [63, 64]. It is therefore rel-
evant to evaluate the impact of race and/or ethnicity on the
pharmacological properties of a new insulin. A eugly-
caemic glucose clamp study of a single dose of IDegAsp in
Japanese patients with T1DM showed that in this patient
population, the glucose-lowering effect profile of IDegAsp
was characterised by separate prandial and basal action
from the IAsp and IDeg components [13]. As also seen in
Caucasian patients with diabetes, the glucose-lowering
effect profile of IDegAsp was elevated relative to the sin-
gle-dose profile when simulated to steady state in Japanese
patients with T1DM [13] (Fig. 10). Furthermore, it
demonstrated a rapid onset and a peak action from IAsp, as
well as a separate and sustained basal glucose-lowering
effect due to IDeg [13] (Fig. 10). It is concluded that the
pharmacodynamic properties of IDegAsp in Japanese
patients with T1DM are consistent with those seen in
Caucasian patients with T1DM.
6 Implications of IDegAsp Pharmacological
Properties in Clinical Use
IDegAsp is the first combination of two individual insulin
analogues delivered in a single pen. IDegAsp provides both
long, flat and stable basal glucose-lowering effect and
prandial insulin coverage, and the pharmacodynamic
properties of IDegAsp are consistent with its individual
components (Sect. 3). The distinct peak and the separate
and flat basal effects are retained during once-daily dosing
as well as twice-daily dosing and appear to be preserved
across several different patient populations, including the
elderly, children, adolescents, Japanese patients and those
with hepatic or renal impairment (Sect. 5). As summarised
in Table 1, in large phase III clinical trials, IDegAsp has
been shown to provide effective glycaemic control,
addressing both fasting and postprandial glucose control,
with a relatively low risk of hypoglycaemia in both insulin-
naı¨ve and insulin-experienced patients with diabetes.
Table 2 presents an overview of the relation between the
various clinical benefits of IDegAsp and its key pharma-
cological properties. The following subsections will
address the clinical applicability of the results obtained in
the IDegAsp phase III trials compared with three other
currently available treatment options: premixed insulin,
basal-bolus regimens and basal-only therapy.
6.1 Comparison with BIAsp 30
The efficacy and safety of IDegAsp have been compared
with those of BIAsp 30 in three trials in insulin-naı¨ve or
insulin-experienced patients with T2DM [16, 17, 19]. Due
to the treat-to-target approach of these trials, IDegAsp
provided effective overall glycaemic control comparable to
























IDegAsp 0.5 U/kg SS
IDegAsp 0.5 U/kg SD
Fig. 10 Mean glucose-lowering effect profiles for 0.5 U/kg IDegAsp
after a single dose and at steady state during once-daily dosing in
Japanese patients with T1DM (modified from Haahr et al. [13]).
IDegAsp insulin degludec/insulin aspart, SD single dose, SS steady
state, T1DM type 1 diabetes mellitus
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BIAsp 30 (Table 1). Fasting plasma glucose (FPG)
reduction was superior for IDegAsp compared with BIAsp
30, which is probably partly a consequence of the extended
duration of action of IDeg in IDegAsp compared with the
protaminated fraction of IAsp in BIAsp 30. Furthermore,
the low within-subject day-to-day variability in glucose-
lowering effect of the IDeg component should allow for
aggressive titration to low FPG targets without being lim-
ited by unacceptable rates of nocturnal hypoglycaemia
(Table 2).
Hypoglycaemic episodes can adversely affect daily
activities such as exercise, work and sleep [65]. The
occurrence of hypoglycaemia and the fear of future epi-
sodes can affect the clinical success of diabetes treatment
and has been highlighted as a reason for aiming at less
ambitious glycaemic targets and for reducing the insulin
dose [2, 66]. In the two global trials comparing IDegAsp
with BIAsp 30, IDegAsp resulted in significantly lower
rates of overall and nocturnal hypoglycaemia [16, 19],
consistent with the results of a meta-analysis of the two
trials in insulin-experienced patients [67]. The reduced risk
of hypoglycaemia with IDegAsp is probably due to its
distinct prandial and basal glucose-lowering effects with no
‘shoulder effect’. The lower day-to-day variability in the
glucose-lowering effect of IDegAsp presumably con-
tributes further to the low rate of hypoglycaemia observed
compared with BIAsp 30 (Table 2).
IDegAsp can be administered once or twice daily with
the main meal(s) and provides the option of flexible timing
of administration as long as it is taken with the largest
meal(s) [46, 47]. The potential for flexible dosing is based
on the extended duration of action of IDeg in IDegAsp,
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Results shown in bold indicate a statistically significant difference between IDegAsp and the comparator
BB basal-bolus, BIAsp 30 biphasic insulin aspart 30, bid twice daily, FPG fasting plasma glucose, HbA1c glycosylated haemoglobin, IAsp insulin
aspart, IDegAsp insulin degludec/insulin aspart, IDeg insulin degludec, IDet insulin detemir, IGlar insulin glargine, od once daily, T1DM type 1
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which implies that during repeated dosing the glucose-
lowering effect at a given time is the sum of overlapping
action from several injections [44]. Variations in the dosing
interval will therefore have limited impact on the glucose-
lowering effect from the basal component of IDegAsp. The
possibility of varying the time of administration from day
to day was confirmed in a clinical trial with IDeg in
patients with T2DM, where dosing intervals of 8–40 h did
not compromise glycaemic control or safety compared with
IGlar administration at the same time each day [68].
As discussed in Sect. 3.4, twice-daily dosing of
IDegAsp may give rise to questions about ‘stacking’
because of the long duration of action of IDeg in IDegAsp.
However, it was concluded that once-daily versus twice-
daily dosing of IDegAsp results in comparable glucose-
lowering effect from the basal component as long as the
same total daily IDegAsp dose is administered. The safety
of IDegAsp in a twice-daily regimen is also indicated from
the clinical trial results showing significantly lower rates of
overall and nocturnal hypoglycaemia with IDegAsp than
with BIAsp 30 administered twice daily. Dependent on the
carbohydrate load of the main meals, some patients fol-
lowing an IDegAsp twice-daily regimen might prefer to
split the daily dose unevenly. This scenario has not been
investigated in clinical trials, but theoretically it would be
expected to have only minor impact on the daily glucose-
lowering effect from the basal component based on the
above discussion of flexible dosing. With twice-daily
dosing of IDegAsp, the minimum interval between doses is
determined by the duration of action of the prandial com-
ponent, and hence would need to be 4–6 h.
Taken together, compared with the widely used pre-
mixed insulin, BIAsp 30, IDegAsp represents a new ther-
apeutic option, both as insulin initiation and for treatment
intensification in patients with T2DM. IDegAsp provides
effective glycaemic control, with a markedly lower risk of
hypoglycaemia, and offers simplicity of use for patients
because resuspension before injection is not needed.
6.2 Comparison with Basal-Bolus Regimens
The burden associated with multiple daily injections is still
one of the most important issues for insulin-treated dia-
betes patients [69]. Accordingly, basal-bolus regimens are
perceived as complex and can induce some patients to
regularly omit insulin [2, 70]. IDegAsp, possibly supple-
mented with rapid-acting insulin at the remaining meals,
represents a simple alternative to separate basal and bolus
injections. In patients with T2DM previously receiving
basal insulin, IDegAsp twice daily was compared with a
basal-bolus regimen of IDeg once daily plus IAsp (Table 1)
[18]. Both intensification regimens were effective in
improving glycaemic control and, even though non-infe-
riority between treatments could not be confirmed, there
were no significant treatment differences that could imply
an effect on clinical usefulness [18]. Nonetheless, total
insulin dose was lower and weight gain was less with
IDegAsp [18]. This indicates that IDegAsp provides an
effective and convenient regimen for those patients with
T2DM who need intensified insulin therapy but at the same
time find it challenging to follow a more complex regimen
with frequent glucose monitoring [71].
Table 2 Clinical benefits of IDegAsp and their relation to IDegAsp pharmacological properties
Clinical benefits Pharmacological properties Relevant section(s) for discussion
of pharmacological properties
Versus premixed
Improved FPG control Duration of action[30 h
Low within-subject day-to-day variability
Section 3.2
Section 3.5
Reduced hypoglycaemia risk No ‘shoulder’ effect
Low within-subject day-to-day variability
Section 3.3
Section 3.5
Mealtime flexibility Duration of action of basal component[30 h
Distinct prandial and basal glucose-lowering effects during
od and bid dosing
Section 3.4
Section 3.4
No need for resuspension Existence of insulin degludec and insulin aspart as separate
and stable soluble forms in the co-formulation
Section 2.3
Versus basal-bolus
Reduced number of daily injections Distinct prandial and basal glucose-lowering effects during
od and bid dosing
Sections 3.2 and 3.4
Versus basal-only
Additional flexible mealtime coverage Distinct prandial and basal glucose-lowering effects during
od dosing
Section 3.2
bid twice daily, FPG fasting plasma glucose, IDegAsp insulin degludec/insulin aspart, od once daily
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Although IDegAsp is particularly suited for patients
with T2DM, trials have shown that it may also be used in
those with T1DM. In patients with T1DM, IDegAsp once
daily was compared with IDet once or twice daily with
IAsp at the remaining meals (Table 1) [14, 20]. IDegAsp
showed similar glycaemic control, comparable rate of
overall hypoglycaemia, reduced risk of nocturnal hypo-
glycaemia and lower total insulin dose, with fewer injec-
tions than with IDet [14, 20]. IDegAsp may not be
suitable in those patients with T1DM who prefer the flex-
ibility of separately titrating the prandial and basal com-
ponents. However, in those patients with T1DM who
would not consider self-adjusting their insulin doses,
IDegAsp may be an option, with fewer daily injections and
thus reduced treatment burden.
6.3 Comparison with Basal-Only Therapy
Treatment guidelines state that early use of insulin therapy
should be considered in patients with T2DM [1]. While
initiation with basal insulin is the most common regimen in
many countries, initiation with premixed or combination
insulin is still a widely used strategy. Addressing post-
prandial hyperglycaemia may be important for achieving
overall glycaemic control, particularly in patients with
HbA1c approaching target [72, 73]. Thus, IDegAsp could
be an option for initiation of insulin, especially in patients
who need to achieve postprandial glycaemic control.
In clinical trials comparing IDegAsp once daily and IGlar
once daily in patients with T2DM, IDegAsp was well tol-
erated and provided similar or improved overall glycaemic
control versus IGlar, with the additional benefit of post-
prandial glucose control at one main meal, and with noc-
turnal hypoglycaemia rates comparable to those observed
with IGlar (Table 1) [15, 21]. In one of the trials, a higher
rate of overall hypoglycaemia was observed with IDegAsp
versus IGlar [21]. This might have been due to the trial
requirement that IDegAsp should always be administered
with the same meal, whereas the largest meal of the day in
terms of carbohydrate load may have shifted from day to
day [21]. When using IDegAsp once daily, changes in dose
and the option to move the injection time to match any
significant daily variations in carbohydrate eating patterns
should be considered to minimise the risk of postprandial
hypoglycaemia. Results of a recent study of IDegAsp once
daily in insulin-naı¨ve patients with T2DM showed that self-
titration of IDegAsp using either a simple algorithm with
fewer self-measured blood glucose measurements or a
stepwise algorithm with longer titration intervals but more
self-measured blood glucose measurements provided com-
parable glucose control [74]. These alternative titration
methods may offer patients a personalised insulin titration
regimen tailored to individual needs [74].
Altogether, it seems that IDegAsp is an attractive
treatment option for initiation of insulin therapy in patients
with T2DM, combining the simplicity of a single injection
with the benefits of addressing both fasting and postpran-
dial glucose control. These advantages of IDegAsp may
encourage patients with T2DM to initiate insulin treatment
earlier and to improve their compliance, thereby possibly
facilitating achievement of glycaemic targets.
7 Conclusions
IDegAsp is the first soluble combination of two insulin
analogues (IDeg and IAsp) designed to provide both basal
and mealtime insulin coverage in one injection. Preserva-
tion of the pharmacokinetic and pharmacodynamic profiles
of the individual components in IDegAsp sets it apart from
conventional premixed insulin products. IDegAsp retains
the clear separation of basal and prandial effects during
both once- and twice-daily dosing. Moreover, the phar-
macological properties of IDegAsp appear to be main-
tained across several different patient populations,
including the elderly, children, adolescents, Japanese
patients and those with hepatic or renal impairment.
Translation of its pharmacokinetic and pharmacodynamic
properties into favourable clinical benefits makes treatment
with IDegAsp superior to premixed formulations, as well
as a viable alternative to basal-only and basal-bolus ther-
apy. Overall, IDegAsp has the potential to address certain
barriers in the treatment and management of patients with
diabetes.
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